How GLP-1 Drugs Affect Gut Motility Throughout the Entire Digestive Tract
In a small case series, 80% of patients on GLP-1 receptor agonists had delayed stomach emptying, and semaglutide users showed the most widespread gut slowdown.
Quick Facts
What This Study Found
Using wireless motility capsule testing, researchers measured transit times throughout the entire digestive tract in 10 patients taking GLP-1 receptor agonists. Delayed gastric emptying was observed in 80% of patients (8 out of 10). Delayed whole-gut transit was seen in 44% of patients.
Notably, the 3 patients on semaglutide at 1 mg had the longest gastric emptying times, the most delayed whole-gut transit, and were the only patients who also showed delayed small bowel transit time. This suggests semaglutide may have more pronounced effects on gut motility compared to other GLP-1 drugs in this series.
Key Numbers
How They Did This
This was a retrospective case series at a single medical center. Researchers reviewed records of 10 patients who were taking GLP-1 receptor agonists and had undergone wireless motility capsule testing — a procedure where patients swallow a small electronic capsule that measures pressure, pH, and transit time as it passes through the stomach, small intestine, and colon.
Why This Research Matters
GLP-1 drugs like semaglutide and tirzepatide are now taken by millions of people. While stomach-slowing effects are well known, this study provides some of the first data showing these drugs may affect motility throughout the entire digestive tract. Understanding this is important for managing side effects like constipation, bloating, and gastroparesis that many patients experience.
The Bigger Picture
Most GLP-1 research on gut motility has focused on the stomach. This study adds to growing evidence that these drugs affect the entire digestive system, not just gastric emptying. As GLP-1 prescriptions surge globally, understanding the full spectrum of gastrointestinal effects becomes clinically important for managing the millions of patients on these medications.
What This Study Doesn't Tell Us
This was a very small retrospective case series with only 10 patients at a single center, so the findings cannot be generalized. There was no control group for comparison. Patients were tested for existing GI complaints (constipation or gastroparesis), which may bias toward those already experiencing motility problems. Different patients were on different GLP-1 drugs at different doses, making direct drug comparisons unreliable.
Questions This Raises
- ?Do GLP-1 drugs slow gut motility equally throughout the digestive tract, or is the effect stronger in certain regions?
- ?Does gut motility return to normal after stopping GLP-1 drugs, and if so, how quickly?
- ?Are the whole-gut motility effects dose-dependent, and does semaglutide truly cause more slowdown than other GLP-1 drugs?
Trust & Context
- Key Stat:
- 80% of patients on GLP-1 drugs had delayed gastric emptying measured by wireless motility capsule
- Evidence Grade:
- This is a retrospective case series with only 10 patients and no control group, representing one of the lowest levels of clinical evidence. While the findings are suggestive, they are preliminary and cannot establish causation.
- Study Age:
- Published in 2025, this is very recent research using modern wireless motility capsule technology to study a timely question about GLP-1 drugs.
- Original Title:
- Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.
- Published In:
- ACG case reports journal, 12(8), e01789 (2025)
- Authors:
- Cymbal, Michael, Naseem, Zehra, Hoxha, Din, Garg, Samita
- Database ID:
- RPEP-10572
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs only slow down the stomach?
This study suggests the effects extend beyond the stomach. While 80% of patients had delayed gastric emptying, 44% also had delayed transit through the entire digestive tract, and semaglutide users showed slowdowns in the small intestine as well.
What is a wireless motility capsule?
It's a small electronic capsule that patients swallow. As it passes through the digestive tract, it measures pressure, pH, and temperature, allowing doctors to track exactly how long food takes to move through each section of the gut.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10572APA
Cymbal, Michael; Naseem, Zehra; Hoxha, Din; Garg, Samita. (2025). Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.. ACG case reports journal, 12(8), e01789. https://doi.org/10.14309/crj.0000000000001789
MLA
Cymbal, Michael, et al. "Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.." ACG case reports journal, 2025. https://doi.org/10.14309/crj.0000000000001789
RethinkPeptides
RethinkPeptides Research Database. "Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointesti..." RPEP-10572. Retrieved from https://rethinkpeptides.com/research/cymbal-2025-impact-of-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.